Contents

Search

prostate-specific antigen (PSA) velocity

Reference interval: - < 0.35 ng/mL/year [1] Principle: - rate of change in serum PSA values Clinical significance: - biopsy on the basis of a PSA velocity > 0.35 ng/mL/yr as some current guidelines suggest would lead to large numbers of additional, unnecessary procedures - optimal predictive PSA velocity* of 0.44 ng/mL/year in Black patients & 1.18 ng/mL/year in non-Hispanic whites - optimal PSA velocity threshold for development of metastases is 1.77 ng/mL/year [2] * predictive value for progression of active surveillance grade 1 prostate cancer to stage 2 or 3

Related

prostate specific antigen (PSA) in serum

General

laboratory analysis

References

  1. Vickers AJ et al An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection JNCI J Natl Cancer Inst (2011), February 24, 2011 PMID: 21350221 http://jnci.oxfordjournals.org/content/early/2011/02/24/jnci.djr028.abstract - Yao SL and Lu-Yao GL The Science and Art of Prostate Cancer Screening JNCI J Natl Cancer Inst (2011), February 24, 2011 PMID: 21350220 http://jnci.oxfordjournals.org/content/early/2011/02/24/jnci.djr047.full
  2. Nelson TJ et al. Association of prostate-specific antigen velocity with clinical progression among African American and non-Hispanic white men treated for low-risk prostate cancer with active surveillance. JAMA Netw Open 2021 May 17; 4:e219452. PMID: 33999164 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779928 - Nyame YA, Porter MP. Prostate-specific antigen screening and active surveillance for high-risk individuals. JAMA Netw Open 2021 May 17; 4:e219711. PMID: 33999169 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2779933